From GlobeNewswire:

Abivax will host a virtual KOL Investor Event on February 6, 2024, to discuss phase 2b clinical data and phase 3 trial design for obefazimod in patients with ulcerative colitis. The event will have presentations from Marla Dubinsky, MD, and Parambir Dulai, MD, along with a live Q&A session.

Obefazimod is Abivax’s lead drug candidate for the treatment of adults with moderately to severely active ulcerative colitis. It is an oral small molecule that enhances the expression of miR-124, which plays a critical role in regulating the inflammatory response. The KOL Investor Event will cover the drug’s ongoing and future clinical development plans, as well as the mechanism of action and clinical data from phase 2b trials.

Marla C. Dubinsky, MD, and Parambir S. Dulai, MD, will be discussing the unmet medical need and current treatment landscape for patients with ulcerative colitis (UC) at the event. They are consultants for Abivax and members of the Steering Committee for the IBD Program.

Abivax is a clinical-stage biotechnology company with a focus on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases. Their lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of ulcerative colitis. More information about the company is available at www.abivax.com.



Read more: Abivax to host KOL Investor Event to review phase 2b